Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure

• DOI: 10.2147/opth.s345324
• Publication Date: 2022-01-03T12:20:24Z
• Authors: David Clark; Paul Karpecki; Anne Marie Salapatek; John D Sheppard; Todd C Brady
• Keywords: Allergic conjunctivitis; Itching

To assess the prophylactic and treatment activity of reproxalap, a novel reactive aldehyde species inhibitor, in real-world model allergen exposure.In randomized, double-masked, vehicle-controlled, crossover Phase 2 trial, 70 adult patients with ≥2 years moderate to severe allergic conjunctivitis history, positive skin test ragweed pollen, chamber-induced ocular itching redness scores ≥2.5 (both scales range from 0 4), respectively, were randomized 1:1:1 one three sequences: 0.25% 0.5% placebo; placebo, reproxalap; or reproxalap. Symptoms conjunctival assessed over 3.5 hours an chamber aerosolized pollen (3500 grains/m3). Test article was administered bilaterally just before entry at 90 minutes after entry.Reproxalap safe well tolerated; 66 enrolled completed all visits. Relative vehicle, both concentrations reproxalap demonstrated statistically significant clinically relevant improvements itching, tearing, duration exposure (P < 0.001 for assessments). Prophylactic drug demonstrated.In chamber, superior vehicle across typical symptoms signs conjunctivitis. These data are among first rigorous clinical results demonstrating improvement exposure.